Effect of Ischemic Postconditioning on Targeting of Annexin A5 After Forearm Exercise


To adjust our forearm model for ischemia reperfusion injury, in order to used it for assessment of ischemia reperfusion damage in elderly and patients. To test the effect of ischemic postconditioning on ischemia reperfusion injury in healthy volunteers, using Annexin binding after repetitive handgripping.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Crossover Assignment
    • Primary Purpose: Diagnostic
    • Masking: None (Open Label)

Detailed Description

Recently, ischemic postconditioning has been identified as a protective intervention against ischemia-reperfusion injury. In animal studies, the signalling pathway of this (impressive) protective phenomenon is very similar to ischemic preconditioning. It opens a new avenue of post-reperfusion interventions with drugs that have been shown to mimic ischemic preconditioning. Before we can study this phenomenon in our forearm ischemia-reperfusion model, we need additional validating experiments. The purpose of this study proposal is to provide these data.


  • Procedure: repetitive short ischemia and reperfusion of non dominant fore arm after 10 minute ischemic exercise

Clinical Trial Outcome Measures

Primary Measures

  • Annexin A 5 targeting in the non dominant thenar muscle after (ischemic exercise), as a indicator for ischemia reperfusion injury.

Secondary Measures

  • Workload during (ischemic) exercise.

Participating in This Clinical Trial

Inclusion Criteria

  • Age 18-50 years – No physical limitation to perform ischemic exercise – Informed consent Exclusion Criteria:

  • Diabetes (fasting glucose > 7,0mmol/l, or random glucose >11,0mmol/l) – hyperlipidemia (random total cholesterol > 6.5 mmol/l) – Hypertension (supine SBP/DBP > 140/90 mmHg at screening) – Any cardiovascular disease – Drug abuse – Concomitant chronic use of medication – Administration of radioactivity in research setting during the last 5 years – Participation to any drug-investigation during the previous month as checked with VIP check according to CRCN standard procedures.

Gender Eligibility: Male

Minimum Age: 18 Years

Maximum Age: 50 Years

Are Healthy Volunteers Accepted: Accepts Healthy Volunteers

Investigator Details

  • Lead Sponsor
    • Radboud University
  • Overall Official(s)
    • Gerard Rongen, MD PhD, Principal Investigator, RUMCN


Rongen GA, Oyen WJ, Ramakers BP, Riksen NP, Boerman OC, Steinmetz N, Smits P. Annexin A5 scintigraphy of forearm as a novel in vivo model of skeletal muscle preconditioning in humans. Circulation. 2005 Jan 18;111(2):173-8. Epub 2004 Dec 27.

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.